<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116151</url>
  </required_header>
  <id_info>
    <org_study_id>Alantel</org_study_id>
    <nct_id>NCT04116151</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Cream for Treatment of Dermatitis in Patients Whith Cancer</brief_title>
  <acronym>Alantel-</acronym>
  <official_title>Effectivenes and Safety of a Cream of Aloe Vera, Camomila and Tomillo (Alantel) for Profilaxis or Treatmment of Deratitis by Radiotheraphy in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Reina Sofia de Cordoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is intended to evaluate the effect of a marketed cream (Alantel®) based on natural
      products at high concentrations for the preventive and curative treatment (early stages) of
      radiation-induced dermatitis in cancer patients. For this, an experimental, prospective,
      controlled clinical trial, with two parallel arms, double blind, multicentre, will be carried
      out in which doctors will recruit 78 patients aged 14 years or over in Primary Care
      consultations. more, diagnosed with cancer, and having received radiotherapeutic cancer
      treatment, being randomly assigned to the experimental group (cosmetic cream) or the control
      group (placebo cream). The main variable will be the incidence rate of mild
      post-translational dermatitis and its improvement or cure once it has been established.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental, prospective, controlled clinical trial, with two parallel arms, double blind, multicenter study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blind: both the patient and the healthcare professional do not know if the cream to be tested or the placebo is applied</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of radiation-induced dermatitis</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analog visual scale</measure>
    <time_frame>three weeks</time_frame>
    <description>Analog visual scale from 0 to 10 points to assess the symptomatology perceived by the patient (pain, stinging, ..)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>DERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH CANCER</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local administration of the Alantel (R) cream on the affected skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Local administration of the Placebo cream on the affected skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)</intervention_name>
    <description>Application on the affected skin of the cream to be tested</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Harmless moisturizing substance</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 14 years of age or older

          -  Diagnosed with cancer and who are or have recently received radiotherapy treatment.

          -  We will include patients without dermatitis or with acute dermal posttradiotherapy
             lesions, in grades 1 and 2.

        Exclusion Criteria:

          -  Patients with dermal lesions in grade greater than 2.

          -  Skin cancer invasion or distant tumor metastasis.

          -  Concurrent chemotherapy with RT, severe / extensive burns, moisture, erosion or
             suppuration in the skin, history of connective tissue disorders, severe mental
             disorder (dementia, drug addiction, etc.).

          -  History of hypersensitivity reaction to any of the ingredients of the studio cream.

          -  Participants involved in other clinical trials within that month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Family Medicine Teaching Unit and Community</name>
      <address>
        <city>Córdoba</city>
        <zip>14011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Reina Sofia de Cordoba</investigator_affiliation>
    <investigator_full_name>Luis A Perula</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>CANCER</keyword>
  <keyword>DERMATITIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

